التفاصيل البيبلوغرافية
| العنوان: |
Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage. |
| المؤلفون: |
Lipski, Michelle, Pasciolla, Stacy, Wojcik, Kevin, Jankowitz, Brian, A Igneri, Lauren |
| المصدر: |
Neurosurgery Resident Research |
| بيانات النشر: |
Kluwer Academic Publishers |
| سنة النشر: |
2022 |
| المجموعة: |
Philadelphia College of Osteopathic Medicine: DigitalCommons@PCOM |
| مصطلحات موضوعية: |
Andexanet alfa, Anticoagulation reversal, Factor Xa inhibitor, Hemostatic efficacy, Intracranial hemorrhage, Prothrombin complex concentrate, Neurosurgery |
| الوصف: |
The purpose of this study was to evaluate and compare clinical outcomes in patients who experienced intracranial hemorrhage (ICH) while taking apixaban or rivaroxaban and were reversed with four-factor prothrombin complex concentrates (4F-PCC) or andexanet alfa (AA). This retrospective cohort included adult patients that received 4F-PCC or AA for the initial management of an apixaban- or rivaroxaban-associated ICH. A primary outcome of excellent or good hemostatic efficacy at 12 h post-reversal was assessed. Secondary outcomes evaluated were change in hematoma volume size at 12 h, functional status at discharge, need for surgical intervention or additional hemostatic agents post-reversal, new thrombotic event within 28 days, 28-day all-cause mortality, discharge disposition, and hospital and intensive care unit lengths of stay. A total of 70 patients were included (4F-PCC, n = 47; AA, n = 23). For the primary outcome analysis, 21 patients were included in the 4F-PCC group and 12 in the AA group. The rate of effective hemostasis was similar between the 4F-PCC and AA groups (66.7% vs 75%, p = 0.62). There were no statistically significant differences between the groups for secondary outcomes, including 28-day mortality (40.4% vs 39.1%, p = 0.92) and thrombotic complications within 28 days of reversal (17.0% vs 21.7%, p = 0.63). In patients who experienced an ICH while taking apixaban or rivaroxaban, 4F-PCC and AA were found to have similar rates of excellent or good hemostatic efficacy. |
| نوع الوثيقة: |
text |
| اللغة: |
unknown |
| العلاقة: |
https://digitalcommons.pcom.edu/neurosurgery_residents/16Test |
| الإتاحة: |
https://digitalcommons.pcom.edu/neurosurgery_residents/16Test |
| رقم الانضمام: |
edsbas.23215A0D |
| قاعدة البيانات: |
BASE |
